Abbott Laboratories (ABT) vs. Galena Biopharma (GALE) Head to Head Analysis
Abbott Laboratories (NYSE: ABT) and Galena Biopharma (NASDAQ:GALE) are both large-cap pharmaceuticals – nec companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation and analyst recommendations.
This table compares Abbott Laboratories and Galena Biopharma’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
Abbott Laboratories has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500. Comparatively, Galena Biopharma has a beta of 1.99, indicating that its stock price is 99% more volatile than the S&P 500.
This is a summary of recent recommendations for Abbott Laboratories and Galena Biopharma, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Abbott Laboratories currently has a consensus price target of $57.64, indicating a potential upside of 3.92%. Galena Biopharma has a consensus price target of $4.00, indicating a potential upside of 1,233.33%. Given Galena Biopharma’s higher probable upside, analysts plainly believe Galena Biopharma is more favorable than Abbott Laboratories.
Insider and Institutional Ownership
71.4% of Abbott Laboratories shares are owned by institutional investors. Comparatively, 20.5% of Galena Biopharma shares are owned by institutional investors. 0.8% of Abbott Laboratories shares are owned by company insiders. Comparatively, 0.8% of Galena Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Abbott Laboratories pays an annual dividend of $1.06 per share and has a dividend yield of 1.9%. Galena Biopharma does not pay a dividend. Abbott Laboratories pays out 87.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Galena Biopharma has increased its dividend for 44 consecutive years.
Valuation & Earnings
This table compares Abbott Laboratories and Galena Biopharma’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Abbott Laboratories||$20.85 billion||4.63||$1.40 billion||$1.21||45.84|
|Galena Biopharma||$9.32 million||1.24||-$23.54 million||($1.76)||-0.17|
Abbott Laboratories has higher revenue and earnings than Galena Biopharma. Galena Biopharma is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.
Abbott Laboratories beats Galena Biopharma on 11 of the 15 factors compared between the two stocks.
Abbott Laboratories Company Profile
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company’s Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.
Galena Biopharma Company Profile
Galena Biopharma, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company’s NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company’s therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient’s own immune system to seek out and attack any residual cancer cells.
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.